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ABSTRACT 
Influence of Lactobacillus rhamnosus Isolated from “Amabere Amaruranu” Cultured Milk 
on Adipogenesis 
by 
Justin Kotala 
This study was performed to test the in vitro effects of a Lactobacillus rhamnosus isolate 
from “amabere amaruranu”, a traditional Kenyan cultured milk, on 3T3-L1 and Caco-2 
cell lines. Cultures of fully mature 3T3-L1 adipocytes were treated with bacterial isolate 
cell extract (CE), filtered spent broth (FSB) from overnight bacterial culture, or with a 
PBS control.  Expression levels of PPAR³ 1 and 2, C/EBP±, and ATGL proteins in 3T3-
L1 cells were upregulated by FSB treatment.  CE treatment did not affect protein 
expression levels.  Expression of MTTP and SREBP-1c proteins in Caco-2 cells showed 
no change with either treatment.  Optical density measurements from Oil-Red-O stained 
3T3-L1 adipocytes increased from PBS control cells to 25µl/ml FSB treated cells; 
measurements were reduced by treatments above 25µl/ml FSB.  In conclusion, filtered 
spent broth prepared from a culture of Lactobacillus rhamnosus, isolated from “amabere 
amaruranu” cultured milk showed PPAR³ 1 and 2, C/EBP±, and ATGL agonistic 
properties.   
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CHAPTER 1 
INTRODUCTION 
Probiotic Definition 
 Prior to 2001, no one definition for the term probiotic was agreed upon.  The 
problem was clear that as the market for probiotics grew, the science behind probiotics 
was lagging behind.  In 2002, a joint Food and Agriculture Organization (FAO)/World 
Health Organization (WHO) working group was assembled to draft effective guidelines 
for the evaluation of probiotics in food.  One of the main recommendations of this group 
was to adopt the definition of a probiotic as “Live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the host” (Joint 
FAO/WHO Working Group 2002).  Other recommendations of this group were to adopt 
guidelines put forth in the report for testing bacterial strains for probiotic qualities, follow 
good manufacturing practices in the manufacturing of probiotic foods, as well as clear 
labelling of probiotic foods including bacterial strains present and any health claims 
(Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics 
in Food 2002).   
In 2008, Dr. Mary Ellen Sanders addressed the lack of oversight that still plagued 
the growing industry.  She acknowledged that even though the FDA is the regulatory 
authority over probiotic products, it does not require a manufacturer of a probiotic 
product to obtain premarket approval of any claims of efficacy or safety of that product 
as long as the product is not marketed as a drug (Sanders 2008).   She concluded that 
the improper use of the term probiotic within the industry could seriously undermine 
consumer confidence, and that further controlled human studies are needed to validate 
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health claims made by probiotic manufacturers (Sanders 2008).  Her paper brought up 
many of the same problems that the joint FAO/WHO working group tried to address 
which could point towards the need for more oversight if the industry cannot regulate 
itself. 
In the past few years, the probiotic industry has experienced unprecedented 
global market growth.  According to a market report by BCC Research, formerly 
Business Communications Company, published in December 2011, the global probiotic 
market which includes sales of probiotic supplements, ingredients, and foods reached 
approximately $21.6 Billion (US) in 2010 and was expected to have a compound annual 
growth rate of 7.6% over the five year period (The probiotics market: Ingredients, 
supplements, foods 2011).  In 2013, a panel of experts from the International Scientific 
Association for Probiotics and Prebiotics (ISAPP) was convened to revisit the definitions 
and guidelines put forth 12 years earlier by the Joint Working Group and provide a 
consensus statement for the appropriate scope and use of the term probiotic.  This 
convention was prompted by the market boom, widespread use of the term probiotic on 
many products that did not meet minimum criteria, and scientific advances within the 
field.  Ultimately, the committee retained the FAO/WHO definition from 2001 and called 
for more scientific evidence to be obtained before labelling a product probiotic (Hill et al. 
2013). 
Role of Probiotics in General Health 
The probiotic industry has exploded over the last five to ten years with many 
probiotic products on the market.  The problem arises that science has not been able to 
keep up with the pace of the market expansion and many of the product claims remain 
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scientifically unverified (Sanders 2008).  With that being said, much work has been 
done to elucidate the beneficial effects of probiotics on the body. 
 With the gut microbiome being implicated in many disease states, probiotics 
have been increasingly studied because of their ability to change the microbial 
community within the gut (Ji et al. 2012).  The idea of modulating the microbiome from a 
disease state to a healthy state to treat gastro-intestinal diseases that currently have 
very limited treatments is enticing.  Much of the early probiotic work was focused around 
alleviating gastrointestinal (GI) diseases.  Meta-analysis of clinical trials involving the 
treatment of infectious diarrhea with rehydration therapy and probiotics showed that 
probiotics significantly reduce the time period of diarrhea in patients treated with 
probiotics (Allen et al. 2004).  When treating symptoms of Irritable Bowel Syndrome with 
probiotics, patients reported higher relief of symptoms than placebo group (Kajander et 
al. 2008).   
 Studies done on the effectiveness of probiotics to treat food allergies and atopic 
dermatitis have shown that probiotics do have an immuno-modulatory role.  Many of 
these studies have been focused around newborns since it is believed that the 
maturation of the immune system is dependent on colonization of the newborn GI tract 
by normal newborn microbiota.  Differences in the microbiome were observed in 
newborns delivered by vaginal delivery as opposed to Cesarean section (Dominguez-
Bello et al. 2010).  Also, antibiotics prescribed to infants alters the microbiome and can 
be linked with higher prevalence for immune mediated diseases such as Irritable Bowel 
Disease (IBD), asthma, and obesity (Zeissig and Blumberg 2014).  Infants with cow’s 
milk allergy, treated with Lactobacillus GG, showed significant decrease in the incidence 
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of atopic dermatitis (Majamaa and Isolauri 1997).  Lactic acid bacteria have been shown 
to reduce cytokine production specific to allergic sensitivity, showing that probiotics can 
have a direct impact on immune cells (Pochard et al. 2002).  It would, therefore, seem 
that probiotics can have a beneficial effect on the overall health of the host. 
Lactobacillus rhamnosus Isolate 
 The potential probiotic used for this study was isolated from “amabere 
amaruranu”, a traditional Kenyan cultured milk.  This isolate was chosen for continued 
testing because Lactobacillus species are generally considered safe for food and 
supplementation (Joint FAO/WHO Working Group 2002).  This isolate was shown to be 
stable in digestive tract conditions, have no ability to degrade mucin, and was sensitive 
to antibiotics.    The isolate was identified as L. rhamnosus by both 16s rRNA and 
biochemical assay (Boyiri et al. 2014).  These tests are recommended by the joint 
FAO/WHO working group to establish a new bacterial isolate as a potential probiotic. 
Human Gut Microbiome in General Health and Disease 
The gastro-intestinal tract is home to a great diversity of microbiota.  There are 
approximately ten times more bacteria in the human gut than eukaryotic cells in the 
human body.  The compilation of this microbiota is still being discovered, but recent 
studies have shown that the gastrointestinal tract is home to over 1200 distinct 
microorganisms (Rajilic-Stojanovic et al. 2007).  Although the exact bacterial 
composition of the gut microbiome is unique to each individual, sequencing of the 
human gut microbiome has shown that the majority of the organisms living in the GI 
tract are members of either the Firmicute or Bacteroidetes phylum (Eckburg et al. 2005).  
The proportions of these two phyla are stable in healthy populations but have been 
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shown to differ significantly in disease states such as obesity (Ley et al. 2006).  This 
diversity begins at birth.  At birth, the neonatal intestine is sterile but immediately 
colonized by bacteria from maternal and environmental sources, and progress to an 
adult-like microbiome as the infant transitions to solid food (Palmer et al. 2007). 
Ilya Metchnikoff was one of the first scientists to suggest that intestinal 
microorganisms might play a role in human health by benefitting the host (O'Toole and 
Cooney 2008).  His ideas were mostly ignored until the 1990’s, when research into the 
gut microbiome and its role in human health gained acceptance.  The human gut 
microbiome has become a topic of focus for research since very little was known about 
it until recently.  New high throughput sequencing techniques have allowed researchers 
to develop new insight into the composition and functionality of the microbiome.  As the 
relationship between the gut microbiome and its human host is better analyzed, 
researchers are coming to realize that the gut microbiome has more effects than just in 
aiding digestion.   
Gut Microbiome in Gastrointestinal Health 
The gut microbiome could be looked at as another organ.  In healthy individuals, 
the microbiome works symbiotically with the host to help facilitate digestion and uptake 
of nutrients from food.  One important function to humans is that it allows for the 
processing and digestion of foods that would be otherwise indigestible, like plant 
polysaccharides (Bergman 1990; Samuel and Gordon 2006)  and gluten (Caminero et 
al. 2014).  Mutualism exists within the microbiome as organisms function to catabolize 
nutrients in the GI tract, which support a healthy diverse microbiome (Samuel and 
Gordon 2006).  This mutualistic role that the gut microbiome plays has allowed for the 
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digestion and metabolism of foods without humans needing to evolve the ability to 
produce specific enzymes for this task.   It has been determined for some time that long 
term lifestyle habits alter the make-up of the gastro-intestinal microorganisms, but now 
research shows that short term shifts in diet can alter the gut microbiome within days of 
such a shift (David et al. 2014).  This same study showed a correlation between diet 
composition, be it plant based or animal based, and changes in bacterial diversity in the 
GI tract.   
 Being that the gut microbiome is integral for proper digestion, it should come as 
no surprise that altered gut microbiomes have been associated with gastrointestinal 
disorders.  Studies done with Celiac Disease (CD) patients show that they have 
elevated levels of both Bacteroides and Clostridium leptum, along with decreased levels 
of Bifidobacterium as compared to healthy control groups (Collado et al. 2009).  Another 
study showed that microbial diversity of fecal samples from untreated CD patients 
cluster together, while fecal samples from CD patients treated with a gluten free diet for 
at least two years show a microbial diversity that reflects that of healthy control subjects 
(Nistal et al. 2012).  These studies point to dysbiosis within the gut microbiota.  It is not 
clear, however, if these changes in the microbiome are caused by the diseases or 
cause the disease state, and more studies are needed to link specific microbial 
signatures to specific diseases (De Palma et al. 2014). 
Gut Microbiome in Immunity and Gut-Brain Axis 
The gut microbiome plays an important role in the development of a mature 
immune system.  Infants born by Caesarian section are at a higher risk of developing 
allergies and asthma (Bager et al. 2008).  Such studies reinforce the idea that 
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mutualism exists between the gut microbiome and the host immune system (Maynard et 
al. 2012).  A recent study suggests that Clostridia, present in normal gut microbiome, 
may play a role in helping to reduce food allergen sensitization through an immune-
regulatory role (Stefka et al. 2014).  This could prove useful in finding a way to prevent 
food allergies or desensitize patients with existing food allergies. 
It has been known for some time that there is a bidirectional flow of information 
between the brain and the gut.  This has been termed the gut-brain axis.  The gut 
microbiome has been shown to play a role in the communication between the brain and 
gut.  This relationship was made apparent with studies of patients with hepatic 
encephalopathy.  Hepatic encephalopathy patients showed signs of improvement after 
administration of antibiotics as well as probiotics (Victor and Quigley 2014).  More 
evidence of a brain-gut microbiome link came from studies showing differences in the 
composition of the gut microbiome of autistic and control siblings (Finegold et al. 2010).  
Additionally, autistic patients reported improved symptoms with antibiotic use (Finegold 
2011).  Stress and gut microbiota dysbiosis has been reported as well.  Stress 
introduced into an animal model was shown to induce changes within the diversity of 
the microbiome as well as innate immune response (Bailey et al. 2011).  The innate 
immune response was not seen when the same experiment was performed with mice 
that had received an antibiotic treatment that reduced the gut microbiota.  This suggests 
that the gut microbiome plays a role in innate immune responses to stress. 
Human Gut Microbiota in Obesity and Type 2 Diabetes 
 As obesity continues to be a major health concern around the world, researchers 
look for ways to therapeutically target the disease.  In the search for a solution to the 
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obesity epidemic, attention has been paid to the gut microbiota and its involvement in 
obesity.  The intestinal microbiota plays a major role in digestion and energy harvest as 
shown through the study of germ free and conventionally raised mice (Backhed et al. 
2004).  Germ free mice have significantly lower total body fat than their wild type 
counterparts, even though the germ free mice were consuming more chow than the wild 
type mice.  Also, the same study showed that the gut microbiota was able to regulate 
gene expression linked to energy harvest.  The link between obesity and gut microbiota 
was revealed when metagenomic sequencing of obese and lean mice showed a 
difference in the makeup of the microbiome.  Obese mice had a higher proportion of 
bacteria of the division Firmicutes, and less of the division Bacteroidetes than lean mice 
(Ley et al. 2005).  This proportional difference of the gut microbiome was also observed 
in obese and lean humans (Ley et al. 2006).    
 To further tease out the contributing factors of obesity, metagenomic and 
biochemical aspects of the obese and lean mouse distal gut microbiome have been 
examined.  The obese microbiome was found to be more capable of harvesting energy 
from the mouse’s diet (Turnbaugh et al. 2006).  This same study showed that this 
increased energy harvest ability was transmissible from obese mice to germ free mice 
by inoculating the germ free mice with the obese microbiota.  Although this does not 
prove causality, it shows that the gut microbiome plays a major role in energy harvest 
and obesity. 
 Gastric bypass surgery has been an effective surgical option for severely obese 
individuals to rapidly lose weight.  Recently, it was proposed that gastric bypass surgery 
works to reduce weight and improve glucose tolerance through a shift in the gut 
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microbiome instead of reducing weight by calorie restriction alone.  In sequencing the 
gut microbiome of patients and mouse models of gastric bypass surgery, a shift in the 
microbiota that altered the energy balance in the host was shown (Liou et al. 2013).  
This study also showed that by transplanting the gut microbiota from mice that had just 
had gastric bypass into germ free obese mice, they were able to induce weight loss in 
the germ free mice.   
 As the main focus of this study is being put on obesity, it is important to note that 
another very serious and related problem is Type 2 Diabetes (T2D).  T2D is associated 
with insulin resistance.  Although there is no clear causality between obesity and T2D, 
obesity can increase the risk of acquiring insulin resistance and subsequent T2D 
through low grade chronic inflammation (Das and Mukhopadhyay 2011).   
Endocannabinoid System in Obesity and Insulin Resistance 
A major question that arises when looking at a correlation between the gut 
microbiome and obesity is how does the microbiome interact with the host systems in 
the presence of the mucosal barrier?  The answer may be in the endocannabinoid 
system (ECS).  The ECS consists of bioactive lipids that are important in controlling 
many physiological functions.  Evidence for a link between the ECS and obesity has 
been shown by knocking out the expression of the bioactive lipid synthesis gene in 
mouse adipocytes, and thereby show that the ECS is responsible for energy 
homeostasis throughout the body (Geurts et al. 2015).  The knockout mice had greater 
total fat mass, body-weight gain and a higher insulin resistance index while maintaining 
the same food intake as control mice.  This same study reinforced the idea of an 
association between adiposity, the ECS and gut microbiome when researchers found 
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significant changes in the gut microbiota of knockout mice.  While a shift in gut 
microbiome was associated with this genetic knockout, long-term antibiotic treatment 
improved body-weight gain, fat mass, and reduced insulin resistance index in knockout 
mice.  Researchers were able to partially replicate the knockout phenotype by 
transferring the gut microbiome from knockout mice into wild type germ free mice.  This 
study strengthens the argument for a correlation between the gut microbiome, ECS and 
obesity. 
Probiotics and Their Influence on Adipogenesis  
The gut microbiome controls many more aspects of the host body than had ever 
been imagined.  Since there are correlations between disease states and shifts in host 
gut microbiome, then disease states should be improved by manipulating the gut 
microbiome into a more normal state.  Research to support this hypothesis showed that 
a lean gut microbiome transferred to an obese mouse will incur significant weight loss 
(Ridaura et al. 2013).  Hence a manipulation of the gut microbiome is a viable method to 
fight diseases that contribute to a disease shifted microbiome.  Probiotics can 
manipulate the gut microbiome and regulate various host systems to improve many 
aspects of a disease. 
A number of probiotic strains have been shown to affect adipogenesis in cell 
culture.  A probiotic isolated from Kimchi, a traditional fermented dish, has inhibitory 
effects on intracellular lipid accumulation in vitro (Moon et al. 2012).  This study treated 
3T3-L1 cell culture with either spent media or cytoplasmic fraction from the culturing of 
the isolated probiotic, Weissella koreensis, a lactic acid bacteria.  They were able to 
show that the probiotic treatment lowered both lipid accumulation inside of the cells, as 
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well as mRNA expression levels of key adipogenic transcription factors.  Another 
probiotic isolated from kimchi called Lactobacillus plantarum KY1032 was also shown to 
maintain probiotic activity and regulate lipid metabolism by testing the cytoplasmic 
fraction in 3T3-L1 cells (Park et al. 2011).  This probiotic significantly downregulated 
adipogenic transcription factors and also lowered lipid content within the adipose cells.   
Cell culture studies are a great way to show proof of concept, but it is important 
to understand how probiotics interact with host systems.  Mouse models work as good 
indicators of how a certain probiotic will interact with a human host.  Different species 
and strains of lactic acid bacteria have been used to elucidate anti-obesity effects.  L. 
gasseri BNR17 was one such bacteria that was shown to reduce levels of leptin and 
insulin while increasing expression of fatty acid metabolism related genes (Kang et al. 
2013).  A similar study used L. rhamnosus PL60 to incur weight loss and reduce white 
adipose tissue deposits in diet induced obese mice (Lee et al. 2006).   
All of these studies have looked at modelling the human obesity condition, but 
even the best models will differ from human physiology.  Therefore it is important to also 
look at human trials to show that probiotics can carry over the anti-obesity effects shown 
in models to human hosts.  In a human trial using adults with obese tendencies, L. 
gasseri SBT2055 was shown to significantly reduce abdominal adiposity as well as 
other markers of obesity (Kadooka et al. 2010).  Another study tested the effects of L. 
acidophilus NCFM to improve insulin sensitivity in male subjects with Type 2 Diabetes.  
The study showed that the probiotic was able to preserve insulin sensitivity compared 
with a control group (Andreasen et al. 2010).  Human trials continue to provide insight 
into new treatments for obesity and Type 2 Diabetes. 
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Probiotic research has improved the collective knowledge of both the human 
body systems as well as how bacteria interact with these systems.  This research has 
shown that many beneficial effects of probiotics are strain specific.  These studies have 
created a precedent for effectively testing novel probiotics and their efficacy in 
regulating adipogenesis.   
Adipogenic Transcription Factors 
 When studying effects of a compound on a biological system, it is important to 
understand how the compound elicits the effect that it has.  To do so, the system can be 
studied at the molecular level to see how the compound affects the protein and gene 
expression levels that drive the biological system.  In this case, adipogenesis is a 
complex interplay between many different genes that regulate each other as illustrated 
in Figure 1.  The present study will focus on four primary transcription factors that have 
been shown to be critical to the maturation of adipose cells and the storage of lipids: 
PPAR³ , C/EBP±, SREBP-1c, and ATGL.  
In order to study the effect of a novel probiotic on the adipogenic pathway, cell 
culture modelling is the most efficient way to begin.  The 3T3-L1 cell line was chosen for 
use in this study.  The 3T3-L1 cell line is an adipocyte lineage that was first established 
in 1975.  This cell line has been used extensively to study the mechanisms of 
adipogenesis because of its similarity to human adipocytes.  Once exposed to a nutrient 
cocktail which includes isobutylmethylxanthine (IBMX), dexamethasone and insulin, the 
preadipocytes will differentiate into mature adipocytes.  This maturation process 
expresses multiple metabolic programs that are characteristic of mature fat cells.  The 
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validity of this cell line as a model of adipocyte formation is supported by many studies 
performed in both mouse and human tissue (Farmer 2006).  
PPAR-³  
 PPAR³  is considered the master regulator of adipogenesis.  Originally thought to 
work co-dependently with C/EBP±, it was shown that PPAR³  alone can induce 
adipogenesis.  This was elucidated by doing both gain of function, and loss of function 
studies on PPAR³ .  Gain of function studies showed that ectopic expression of PPAR³ 2 
in multiple fibroblast cell lines caused them to differentiate into adipocytes (Tontonoz et 
al. 1994b).  The loss of function study was done by Rosen and collegues, and involved 
using embryonic stem (ES) cells that lacked a normal PPAR³  gene.  These cells were 
not able to differentiate into adipose cells in vitro (Rosen et al. 1999).  Rosen’s study 
also used a chimeric mouse model to show that mice not expressing PPAR³  could not 
produce adipose tissue.   
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Figure 1.  A pathway map of adipogenesis.  Key points from this map are that PPAR³ 2 
is the bottleneck point for the differentiation process.  SREBP-1c is directly influenced 
by insulin.  C/EBP± forms a positive feedback loop with PPAR³ 2 to maintain expression 
in mature adipocytes.  The four transcription factors focused on in this project are 
outlined in bold.    
 PPAR³  is expressed in adipose cells as two isoforms, PPAR³ 1 and PPAR³ 2.  
Both isoforms are exactly the same except that the PPAR³ 2 isoform contains an 
additional 30 amino acids at the amino terminus (Tontonoz et al. 1994a).  Tontonoz and 
colleagues showed that while PPAR³ 1 is expressed in several different types of tissue, 
PPAR³ 2 is specific to adipocytes.  PPAR³ 2 was shown to be the critical transcription 
factor that regulated cellular differentiation and lipid storage during adipogenesis (Ren 
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et al. 2002).  Ren and colleagues developed a knockout study that showed clearly that 
PPAR³ 1 expression without PPAR³ 2 expression could not trigger adipogenesis in 3T3-
L1 cells, therefore showing conclusively that PPAR³ 2 is crucial for adipogenesis.   
PPAR³  is the target for a class of antidiabetic drugs called thiazolidinediones.    
How this class of drugs worked was unclear until Lehmann and colleagues showed that 
Thiazolidinediones are direct agonists for PPAR³  (Lehmann et al. 1995).  This class of 
drugs, which includes Rosiglitazone, is used to treat Type 2 Diabetes.  Although these 
drugs are effective at controlling blood glucose levels in patients with Type 2 Diabetes, 
they are known for having many side effects.  Other effective methods for treating Type 
2 Diabetes with less side effects are needed. 
C/EBP± 
 CCAAT/Enhancer-binding Protein ± is another critical transcriptional regulator of 
adipogenesis.  Once assumed to be equal to PPAR³  in its role as a master regulator, it 
was shown to not be as important as PPAR³  in regulating the entire pathway.  With that 
being said, C/EBP± has been shown to be critical in conveying insulin sensitivity to the 
mature adipocyte.  Wu and colleagues were able to show that PPAR³  activates 
expression of C/EBP±, which then enters a positive feedback loop with PPAR³  ensuring 
terminal differentiation and high-level expression of both genes in differentiated cells 
(Wu et al. 1999).  The differentiation pathway for creating mature adipocytes is not fully 
understood.  What is now known is that as C/EBP²  is needed to bind to the C/EBP± 
promoter site, but cannot induce transcription without the presence of PPAR³  (Zuo et al. 
2006). 
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 In addition to positively regulating PPAR³ , C/EBP± is critically important in 
conferring insulin sensitivity to the mature adipocyte.  During C/EBP± knockout studies, 
it was observed that the mature adipocytes had no insulin-stimulated glucose transport 
(Wu et al. 1999).  C/EBP± is responsible for the expression of many insulin sensitivity 
factors such as GLUT4, as well as fatty acid transporter, FAT/CD36 (Qiao et al. 2008).  
ATGL 
 Adipose Triglyceride Lipase (ATGL) was first identified in 2004 by three 
independent research groups.  It is expressed predominantly in both white and brown 
adipose tissue and localizes on the lipid droplets (Zechner et al. 2005).  This enzyme 
has high substrate specificity for triacylglycerol (TG) and is responsible for the first step 
in lipolysis, hydrolyzing TG into Diacylglycerol (DG) and fatty acid (FA) (Zimmermann et 
al. 2004).  Before this discovery, the enzymes hormone-sensitive lipase (HSL) and 
monoglyceride lipase (MGL) were thought to be the main enzymes that drive lipolysis.  
MGL performs the last step in the pathway of hydrolyzing monoglycerides into glycerol 
and FA.  HSL was known to have broad substrate specificity to lipid esters.  HSL 
knockout studies had shown that there were other enzymes involved in the pathway 
though.  ATGL completed the pathway becoming the rate limiting enzyme for the 
process of TG mobilization (Chakrabarti and Kandror 2011).   
 ATGL levels vary during feeding and fasting.  Both the mRNA and protein 
concentrations are affected by nutritional status.  ATGL activity has been shown to be 
regulated through both gene expression and post-translational modification (Chakrabarti 
and Kandror 2011).  The ATGL transcript was shown to be downregulated by insulin 
during refeeding periods, as well as downregulated due to treatment with TNF-± and is 
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a direct transcriptional target of PPAR³  (Kim et al. 2006).  Apart from being regulated at 
the transcriptional level, ATGL is also regulated post-transcriptionally by the lipid protein 
Comparative Gene Identification 58 (CGI-58).  CGI-58 binds to the lipid droplet by 
interacting with perilipin A when the cell is not stimulated.  Once the adipocytes are 
stimulated, the CGI-58 dissassociates from the lipid surface and perilipin A to enter the 
cytosol where it interacts with ATGL protein to activate lipolysis (Zechner et al. 2009). 
  ATGL knockout studies showed that there was a significant reduction of FA 
released from adipose tissue and increased fat accumulation throughout all tissue in the 
knockout animal (Zechner et al. 2009).  This was contrary to what was seen during 
HSL-knockout studies which showed a decreased fat mass in those animals.  This 
indicates that ATGL is critical for maintaining FA levels within the body.  Also contrary is 
that total cholesterol and HDL cholesterol concentrations are reduced in ATGL 
knockouts but raised in HSL knockouts.  Human cases of ATGL deficiency have been 
reported.  These cases arise from a mutation within the ATGL gene that leads to the 
expression of a truncated, but still enzymatically active, protein.  Like ATGL knockout 
mice, these patients present with systemic tryglyceride accumulation along with cardiac 
myopathy but do not develop insulin resistance (Lass et al. 2011). 
SREBP-1c 
 Sterol Regulatory Binding Protein-1c is a transcription factor that is primarily 
expressed in the liver, white adipose tissue, adrenal gland and brain (Shimomura et al. 
1997).  It is primarily responsible for expression of lipogenic genes.  Genetic knockout 
studies showed that SREBP-1c regulates the expression of the lipogenic genes such as 
glucose-6-phosphate dehydrogenase and glycerol-3-phosphate acyltransferase as well 
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as cholesterol enzyme Fatty Acid Synthase (Liang et al. 2002).  This makes SREBP-1c 
a key player in cholesterol and fatty acid metabolism, both important to patients with 
T2D.  In obesity and T2D, glucose and free fatty acids are not stored properly in 
adipose tissue, allowing them to continue in high levels in the blood and store in other 
tissues. 
 The balance of metabolic energy is a complex, closely regulated balance 
between a fasting and fed state.  Adipose tissue is the main site for excess energy 
storage, where in energy excess, triglycerides are built and stored.  During energy 
depletion, these energy stores are broken down into free fatty acids and released into 
the bloodstream.  The switch between fasting and fed state is primarily controlled by 
insulin levels, which is released in response to blood glucose levels.  An increased 
insulin level signals a fed state whereas a low insulin level is indicative of a fasting state.  
Insulin was shown to be a direct agonist for SREBP-1c (Azzout-Marniche et al. 2000).  
The introduction of insulin into cultured cells caused the rapid synthesis of SREBP-1c 
thereby triggering increased expression of other lipogenic genes needed for energy 
storage. 
Lipid Absorption and Transport by Intestinal Epithelial Cells 
 The gastrointestinal lumen is the gateway through which dietary fats are 
absorbed and a physical barrier to the gut microbiome.  Because of the importance of 
the gastrointestinal lumen in nutrient and drug absorption, it is the target of many 
studies.  Due to the fact that lipids are transported through the lymphatic system 
whereas water soluble compounds are transported through the hepatic system, lipid 
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transport is an enticing option to increase drug bioavailability by avoiding the first pass 
effect of the hepatic system (Nauli and Nauli 2013).    
Lipids are first absorbed by enterocytes in the gut lumen as part of the nutrient 
absorption process.  The enterocytes then package the lipids into chylomicrons and 
secrete them into the lymphatic system where they are hydrolyzed and absorbed by 
other tissues.  For this packaging and transport to occur, a well-controlled pathway is 
triggered to transport the lipids to the Endoplasmic reticulum of the luminal cell where 
Microsomal Triglyceride transfer protein forms a chylomicron.  Figure 2 illustrates the 
pathway for fatty acid absorption into the luminal cell and chylomicron synthesis in the 
Endoplasmic Reticulum.  Chylomicrons are transported through the cell and exocytosed 
into the lamina propria and into the lymphatic system.  They travel through the lymphatic 
system eventually entering the bloodstream and are broken down into components by 
endothelial cells (Dash et al. 2015). 
29 
 
 
Figure 2:  The pathway for fatty acid absorption and chylomicron production is a 
complex, closely regulated process.  Fatty acids and cholesterol are absorbed through 
the brush border and transported to the ER where MTTP begins the process of 
synthesizing a chylomicron.  The chylomicron is transported to the golgi where it 
matures and is exported to the lymphatic system.  Image from (Pan and Hussain 2012). 
Biochim. Biophys.Acta 1821:727–35 (116) 
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The gastrointestinal tract has been the target of many studies to understand 
nutrient absorption and its role in obesity.  An effective way to lower plasma triglyceride 
levels would be to reduce the uptake of them from the gastrointestinal lumen.   One 
such study showed that polyphenol-rich black chokeberry extract has the ability to 
regulate gene expression, notably reducing SREBP-1c and other lipid metabolism 
genes in a dose dependent manner in enterocytes (Kim et al. 2013).  This study 
indicates that lipid metabolism and chylomicron production could be altered by a natural 
extract.  Another study was able to show that short chain fatty acids reduced the export 
of lipids and cholesterol out of the small intestine by reducing the expression of 
microsomal triglyceride transfer protein (MTTP) (Marcil et al. 2003).  Even though it is 
not clear whether the probiotic extract being studied possesses hypolipidemic qualities, 
the presence of reduced expression of genes linked to lipid metabolism and 
chylomicron production would strengthen the argument that probiotics could be an 
effective alternative treatment for obesity and Type 2 Diabetes 
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CHAPTER 2 
MATERIALS AND METHODS 
Isolation of L. rhamnosus and preparation of filtered Spent Broth (FSB) and Cell Extract 
(CE) 
 L. rhamnosus was previously isolated and identified, using both 16S rRNA 
sequencing and biochemical testing, from “amabere amaruranu” a Kenyan cultured milk 
source (Boyiri et al. 2014).  The L. rhamnosus isolate was cultured in deMan-Rogosa-
Sharpe (MRS) broth and incubated at 37⁰C for 24 hours until they reached an optical 
density of 2.0 at 550nm or approximately 1.0x109 cfu/ml.  At that time the bacterial broth 
culture was centrifuged at 1100g for 15 minutes at 4⁰C to separate spent broth from live 
bacteria.   
The supernatant was decanted to collect the spent broth.  At this point, the spent 
broth was at a low pH due to the growth of lactic acid bacteria.  The spent broth was 
raised to a pH of 7.4 using NaOH and filtered using a 0.22µm filter.  FSB was then used 
to treat the differentiating adipocytes.  
The bacterial pellet was resuspended in 50ml of PBS. The bacterial suspension 
was sonicated 5 times at 44% amplitude for 2 minutes with 6 minutes of rest.  The 
sonicate was then centrifuged at 1100g for 15 minutes at 4⁰C.  The supernatant was 
collected, filtered through a 0.22µm filter, and labelled CE.  The CE was used to treat 
the differentiating adipocytes. 
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To test for the presence of heat-labile proteins, FSB was heated to produce heat 
inactivated broth (HIB).  To do this, FSB was heated in a water bath at 95⁰C for 10 
minutes. 
Growth of 3T3-L1A Adipocyte Cells 
To test the effects of the probiotic on adipogenesis, the bacteria and bacterial 
extracellular products were tested on an adipocyte 3T3-L1A cell line.  The fibroblastic 
preadipocytes were grown to confluence in Dulbecco’s Modified Eagles Medium 
(DMEM) containing high glucose supplemented with 10% Fetal Bovine Serum (FBS) 
and 100µg/ml Penicillin/Streptomycin at 37⁰C and 5%CO2.  Two days after the cells 
reached full confluence, a differentiation cocktail of 1µg/ml Insulin, 1µM 
Dexamethasone, 0.5mM 3-isobutyl-1-methylxanthine (IBMX), and 2µM Rosiglitazone 
was introduced to the cell growth medium.  The cells were incubated for 48 hours in this 
differentiation medium.  After that time, the medium was changed to growth medium 
containing only 1µg/ml insulin and allowed to incubate 48 hours.  After 48 hours in 
growth medium containing insulin, the cells were incubated for the remainder of the time 
in fresh growth medium.  Media was changed every 48 hours until harvest on day 10. 
The cells were harvested using a cell scraper 10 days after differentiation and 
were lysed using RadioImmuno-Precipitation assay (RIPA) buffer.  The cell lysate was 
sonicated and centrifuged at 12,000 rpm for 20 minutes to separate any unwanted cell 
fragments from the proteins.  The proteins were then collected as the lysate supernatant 
and stored at -80 p C for future assays. 
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Treatment of Differentiating Adipocytes 
To test the dose dependent effects of the probiotic treatment, differentiating 
adipocytes were treated with different concentrations of FSB or CE (10, 25, 50, 75, or 
100µl/ml of media) added to the growth media.  The treatment was started at 
differentiation day 0 and continued for 10 days.  New treatment was added at every 
media change.  PBS was used as a negative control.   
Growth of Caco-2 Cells 
 Caco-2 cells were grown in DMEM containing high glucose media supplemented 
with 10% FBS and 100µg/ml Pen/Strep until reaching confluence at 37⁰C and 5% CO2.  
Once confluent, the cell culture was allowed to continue growth until 14 days after 
confluence in which the cells had spontaneously differentiated to resemble the lining of 
the small intestine.  At this time the cells were treated with different concentrations of 
FSB, CE, or PBS control for 24 hours and then harvested using a cell scraper and lysed 
using RIPA buffer.  The cell lysate was sonicated and centrifuged at 12,000 rpm for 20 
minutes to separate any unwanted cell fragments from the proteins.  The proteins were 
then collected as the lysate supernatant and stored at -80 p C for future assays. 
Quantification of Lipid Present in Adipocytes by Oil-Red-O Staining 
 Intracellular lipid accumulation was measured using Oil-Red-O staining.  The 
3T3-L1A cells were cultured as described above.  At the time of differentiation, they 
were treated with differing concentrations of FSB or PBS as a control.  After 10 days the 
cell plates were collected, growth medium removed and 10% formaldehyde added to 
the wells for 5 minutes.  After 5 minutes, the old formaldehyde was removed and fresh 
formaldehyde added and allowed to sit for at least 1 hour.  After this the formaldehyde 
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was removed and wells washed with 60% isopropanol and allowed to dry completely.  
At this point, Oil-Red-O working solution was added to the wells and left to sit for 10 
minutes.  The Oil-Red-O was removed and distilled H2O was immediately added to the 
wells.  The wells were washed with water until no more red flakes were observed in the 
waste water and left to dry.  At this point the cells were observed under microscopy for 
appearance of stained lipid droplets in the cells. 
 To quantify the lipid content in the wells, the Oil-Red-O was eluted by adding 
100% isopropanol to the wells and letting it sit for 10 minutes.  The isopropanol was 
then pipetted several times to remove all stain from the wells and transferred to a 
spectrophotometric cuvette.  The stained isopropanol was measured by 
spectrophotometry for optical density at 500nm. 
Western Blot Analysis 
 3T3-L1A cells were treated with differing concentrations of FSB, CE, or PBS 
control at time of differentiation and then continuously for 10 days.  After 10 days they 
were harvested and lysed using RIPA buffer and protein content measured using 
bicinchoninic acid assay (BCA).  To ensure uniform concentrations, all samples were 
diluted down to a protein concentration of 2.0 mg/ml as measured by BCA.  Protein was 
separated by running through 10% SDS-PAGE gel and transferred to PVDF 
membranes.  The membranes were blocked using 5% nonfat milk in Tris-Buffered 
Saline with Tween-20.  They were then incubated with various antibodies against 
PPAR³ , C/EBP±, ATGL, and SREBP-1c (Cell Signaling).  Chemiluminescense was 
developed using the SuperSignal West Femto chemiluminescense kit (Thermo).   
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 Analysis of the effects of FSB on Caco-2 cells was performed by measuring 
expression of Fatty Acid Synthase (FAS), Microsomal Triglyceride Transfer Protein 
(MTP), and SREBP-1c.  Western blots were run as described above, and incubated 
against antibodies to these proteins.   
Alphaview software was used to quantify all Western blot images.  All data was 
reported in relative intensity compared to control bands. 
Statistical Analysis 
 Statistical Analysis Systems (SAS) software was used to analyze quantitative 
data.  One way ANOVA was run on the quantified western blot data.  Individual data 
points were compiled and represented as Least Square means. 
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CHAPTER 3 
RESULTS 
Effects of Probiotic Treatment on 3T3-L1A Cells 
 To measure the effect of various levels of the probiotic treatment, Western Blot 
analysis was performed on various transcription factors that are important in regulating 
adipogenesis and lipid storage in adipocytes.  3T3-L1A cells were treated with either 
Filtered Spent Broth or Cell Extract of L. rhamnosus cultures in varying doses (0, 10, 25, 
50, 75, or 100µl/ml) at differentiation and the protein concentration was measured.  The 
values for the Western Blot were quantified by measuring the band intensity relative to 
the control band.  Therefore all values are presented as fold changes compared to the 
control band.   
PPAR³ 1  
 PPAR³ 1 protein expression levels were increased in response to treatment with 
FSB roughly in a dose dependent manner.  Expression levels showed 1.2 to 3.1 fold 
increase when compared to control levels as shown in Table 1.  Table 2 shows the 
mean expression levels of PPAR³ 1 when treated with CE.  As both Table 2 and Figure 
4 show, there was no change in the expression levels of PPAR³ 1 or PPAR³ 2 after 
treatment with CE.  The upregulation of protein expression following FSB treatment was 
a contrast to the no expression change when CE treatment was applied.  The Western 
Blot shows that FSB treatment does induce increased expression of PPAR³ 1, while CE 
treatment had no effect. 
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 Figure 3: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of PPAR³ 1 in 3T3-L1A adipocytes.  Figure 3a is the 
western blot image.  Figure 3b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 0 
µl/ml.  Each bar represents mean fold change values.  The Y-axis has been set to 1 to 
normalize the graph to the control.   
Table 1: Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of PPAR³ 1 in 3T3-L1A adipocytes 
FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.235  
25µl/ml  1.449  
50µl/ml  2.276  
75µl/ml  3.094  
100µl/ml  2.452  
a Protein expression values are of mean fold change.  n=3 to 7.  Mean fold changes 
are of protein expression relative to the positive control.   
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Figure 4: Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on 
the protein expression of PPAR³ 1 in 3T3-L1A adipocytes.  Figure 4a is the western blot 
image.  Figure 4b represents the quantification of the protein expression.  Expression is 
presented as fold change relative to the control CE concentration of 0µl/ml.  Each bar 
represents mean fold change.  The Y-axis has been set to 1 to normalize the graph to 
the control. 
Table 2:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on 
the protein expression of PPAR³ 1 in 3T3-L1A adipocytes  
CE concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.14  
25µl/ml  0.958  
50µl/ml  0.907  
75µl/ml  1.144  
100µl/ml  0.925  
a Expression values are mean fold change.  n = 1 to 3.  Mean fold changes are of 
protein expression relative to the positive control. 
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PPAR³ 2 
PPAR³ 2 expression levels show a 1.2 to 3.0 fold increase in response to 
treatment with FSB (Table 3 and Figure 5).  Table 3 shows that the mean values of the 
protein expression were almost identical to PPAR³ 1 levels. Table 4 and Figure 6 show 
that CE did not affect PPAR³ 2 expression levels as evident by no change in mean 
treated values from control.  Like PPAR³ 1, ³ 2 expression was upregulated by the FSB 
but not CE which indicates that a component present in the FSB can interact with 
differentiating adipocytes to increase PPAR³  protein expression. 
 
 
Figure 5:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes.  Figure 5a is the 
western blot image.  Figure 5b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 
0µl/ml.  Each bar represents mean fold changes.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
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Table 3:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes 
a Expression values are mean fold change. n = 3 to 7.  Mean fold changes are of protein 
expression relative to the positive control. 
 
 
Figure 6:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture 
on the protein expression of PPAR³ 2 in 3T3-L1A adipocytes.  Figure 6a is the western 
blot image.  Figure 6b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control CE concentration of 0 
µl/ml.  Each bar represents mean fold changes.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
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FSB Concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.181  
25µl/ml  1.545  
50µl/ml  2.276  
75µl/ml  3.013  
100µl/ml  2.461  
0      10      25     50      75     100  µl/ml CE  
Figure 6a 
Figure 6b 
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Table 4:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on 
the protein expression of PPAR³ 2 in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 1 to 3.  Mean fold changes are of 
protein expression relative to the positive control. 
 
C/EBP±  
C/EBP± is downstream of PPAR³  and is responsible for many aspects of insulin 
sensitivity within the adipocyte.  The Western Blot data revealed that the FSB treatment 
did impart some upregulation of this protein expression but not to the extent of the 
PPAR³  expression.  Protein expression was recorded at a 1.3 to 1.9 fold increase due 
to FSB treatment (Table 5, Figure 7).  There was a slight increase in expression with 
higher doses of CE treatment, specifically a 1.3 fold increase at 100 µl/ml CE treatment 
(Table 6, Figure 8). 
 
 
 
 
 
CE concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.058  
25µl/ml  0.89  
50µl/ml  0.874  
75µl/ml  1.082  
100µl/ml  0.839  
0      10     25      50   75   100  µl/ml FSB  
Figure 7a 
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 Figure 7:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of C/EBP± in 3T3-L1A adipocytes.  Figure 7a is the 
western blot image.  Figure 7b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 0 
µl/ml.  Each bar represents mean fold change.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
Table 5:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the protein expression of C/EBP± in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 1 to 6.  Mean fold changes are of protein 
expression relative to positive control. 
 
 
FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.949  
25µl/ml  1.321  
50µl/ml  1.674  
75µl/ml  1.757  
100µl/ml  1.866  
0          10        25        50        75       100  µl/ml CE  
Figure 8a 
Figure 7b 
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Figure 8:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture 
on the protein expression of C/EBP± in 3T3-L1A adipocytes.  Figure 8a is the western 
blot image.  Figure 8b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control CE concentration of 0 
µl/ml.  Each bar represents mean fold changes.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
Table 6:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on 
the protein expression of C/EBP± in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 1 to 2.  Mean fold changes are of protein 
expression relative to the positive control. 
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CE concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.09  
25µl/ml  1.065  
50µl/ml  1.046  
75µl/ml  1.291  
100µl/ml  1.344  
Figure 8b 
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ATGL 
Western Blot analysis revealed that ATGL had the highest increase in protein 
expression due to FSB, with fold increases ranging from 1.2 to 3.2 times greater than 
control (Table 7, Figure 9).  In contrast, ATGL also showed the lowest decrease in 
protein expression due to treatment with CE, with expression levels as much as 2 times 
lower than control values (Table 8, Figure 10).  CE treatment was only able to decrease 
ATGL expression levels. 
 
 
 
 
 
 
Figure 9:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the expression of ATGL in 3T3-L1A adipocytes.  Figure 9a is the western blot 
image.  Figure 9b represents the quantification of the protein expression.  Expression is 
presented as fold change relative to the control FSB concentration of 0 µl/ml.  Each bar 
represents mean fold changes.  The Y-axis has been set to 1 to normalize the graph to 
the control. 
 
Figure 9b 
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Table 7:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the expression of ATGL in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 3 to 8.  Mean fold changes are of protein 
expression relative to the positive control. 
 
 
 
 
 
 
Figure 10:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture 
on the expression of ATGL in 3T3-L1A adipocytes.  Figure 10a is the western blot 
image.  Figure 10b represents the quantification of the protein expression.  Expression 
is presented as fold change relative to the control CE concentration of 0 µl/ml.  Each bar 
represents mean fold changes.  The Y-axis has been set to 1 to normalize the graph to 
the control. 
FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.928  
25µl/ml  1.151  
50µl/ml  2.214  
75µl/ml  3.234  
100µl/ml  2.516  
0     10     25    50    75   100  µl/ml CE 
Figure 10a 
Figure 10b 
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Table 8:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture on 
the expression of ATGL in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 1 to 5.  Mean fold changes are of protein 
expression relative to the positive control. 
SREBP-1c 
SREBP-1c expression levels were increased by FSB treatments to 1.2 to 1.4 
times higher than seen with control treatment (Table 9, Figure 11).  Unlike other protein 
expression levels which showed a dose response curve when plotted, SREBP-1c 
expression data after FSB treatments created a bell curve when plotted, with the 
highest expression level coming from 50 µl/ml of FSB treatment.  CE treatment 
increased SREBP-1c expression levels 1.2 to 1.3 times control levels (Table 10, Figure 
12).  Dose response seemed to be absent with this treatment as all of the different 
doses except 50 µl/ml increased expression to roughly the same level.  
 
 
 
 
CE concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.957  
25µl/ml  0.872  
50µl/ml  0.585  
75µl/ml  0.709  
100µl/ml  0.598  
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Figure 11a  
 
Figure 11:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the expression of SREBP-1c in 3T3-L1A adipocytes.  Figure 11a is the 
western blot image.  Figure 11b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 0 
µl/ml.  Each bar represents mean fold changes.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
Table 9:  Effect of filtered spent broth (FSB) from a Lactobacillus rhamnosus overnight 
culture on the expression of SREBP-1c in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 7 to 15.  Mean fold changes are of protein 
expression relative to the positive control. 
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FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.99  
25µl/ml  1.284  
50µl/ml  1.442  
75µl/ml  1.225  
100µl/ml  1.07  
Figure 11b 
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Figure12:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture 
on the expression of SREBP-1c in 3T3-L1A adipocytes.  Figure 12a is the western blot 
image.  Figure 12b represents the quantification of the protein expression.  Expression 
is presented as fold change relative to the control CE concentration of 0µl/ml.  Each bar 
represents mean fold changes.  The Y-axis has been set to 1 to normalize the graph to 
the control. 
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Figure 12a 
Figure 12b 
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Table 10:  Effect of cell extract (CE) from a Lactobacillus rhamnosus overnight culture 
on the expression of SREBP-1c in 3T3-L1A adipocytes 
a Expression values are mean fold changes.  n = 1 to 7.  Mean fold changes are of protein 
expression relative to the positive control. 
 
Comparing PPAR³  Agonistic Ability of Probiotic Extract with Rosiglitazone 
The initial Western Blot data suggested that PPAR³ , and to a lesser degree 
C/EBP±, were upregulated by FSB treatment.  The next step was to compare the 
agonistic ability of FSB treatment to a known PPAR agonist, rosiglitazone.  
Rosiglitazone was being used as a part of the cell culture differentiation treatment to 
produce high differentiation rates.  For this part of the study, rosiglitazone was excluded 
from media of cells being treated with FSB, thus allowing the comparison of adipogenic 
protein expression in cells treated with FSB and cells treated with a thiazolidinedione. 
Table 11 shows the results of the Western blot.   
 
 
 
CE concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  1.155  
25µl/ml  1.183  
50µl/ml  0.975  
75µl/ml  1.291  
100µl/ml  1.344  
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Figure 13.  Western blot image of comparative FSB and rosiglitazone treatments.  
Treatment numbering is as follows:  1 = 0 FSB/No Rosiglitazone, 2 = 0 
FSB/Rosiglitazone, 3 = 50 FSB/No Rosiglitazone, 4 = 100 FSB/No Rosiglitazone. 
Table 11: Comparison of PPAR³  Expression levels from FSB treatment and 
Rosiglitazone 
 
  
 
 
Western blot analysis revealed the possible PPAR³  agonistic quality of FSB.  FSB 
produced similar enhanced PPAR³  expression as Rosiglitazone, a known PPAR³  
agonist.   
 Analysis of the cell culture treated with FSB without Rosiglitazone showed that 
the FSB treatment increased PPAR expression levels from control cells without 
Rosiglitazone.  The analysis also showed that FSB treatment was able to upregulate 
PPAR expression to levels comparable to cells treated with Rosiglitazone.  This 
indicates that the FSB treatment has comparable PPAR agonistic qualities to that of 
known PPAR agonists. 
        Treatment PPARγ Expression 
0 FSB/No Rosiglitazone 1 
0 FSB/Rosiglitazone 1.75 
50 FSB/No Rosiglitazone 2.01 
100 FSB/No Rosiglitazone 2.04 
  1        1       3       3        4        4        2      2    
Figure 13 
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Testing Heat Inactivated Broth for Adipogenic Potential   
To examine the possibility that the FSB contained a heat labile biomolecule, the 
FSB was boiled to denature any possible secreted proteins and then used as a cell 
culture treatment.  Western blot analysis of PPAR³  and ATGL expression showed that 
heat inactivated the active component in the FSB treatment.  Expression levels for both 
proteins were reduced to levels below control treatment (Tables 11 and 12). 
 
 
 
Figure 14a. Western blot image of PPAR³  1 and 2 after HIB treatment.   
14b. Western blot image of ATGL after HIB treatment. 
Table 12:  Effect of heat inactivated broth (HIB) on Expression of PPAR³ 1, PPAR³ 2, 
and ATGL   
Table 12 shows the results of PPAR³  Western blot analysis on HIB treated cell culture.  
Expression levels for both ³ 1 and ³ 2 under HIB treatment were reduced from observed 
  Treatment ³ 1 Expression ³ 2 Expression ATGL Expression 
0µl/ml 1 1 1 
10µl/ml -1.96 -1.68 -1.53 
25µl/ml -3.02 -2.92 -1.46 
50µl/ml -3.38 -2.06 -1.4 
75µl/ml -1.15 -1.52 -1.93 
100µl/ml -2.42 -2.06 -3.11 
Ppar³ 2 
Ppar³ 1 
ATGL 
   0        10       25       50       75       100  µl/ml FSB    
Figure 14a 
14b 
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values for FSB treatment.  Expression of ATGL under HIB treatment was reduced from 
the observed values for FSB treatment.   
 
Oil-Red-O Staining and Quantification of Lipid Content 
An Oil Red O test was performed to measure the lipid content of each well.  The 
data collected indicates that there was a slight rise in lipid content with the 10 and 
25µl/ml FSB treatment. A gradual drop in lipid content was observed after 50µl/ml FSB 
treatment.  Cell death due to FSB treatment over 25µl/ml FSB treatment was observed 
with this experiment.  Lower cell density could contribute to the lower than expected 
lipid content of the cells. 
 
Figure 15:  Oil-Red-O (ORO) staining and quantification by spectrophotometry of lipid 
content of mature 3T3-L1A cells treated with filtered spent broth (FSB) from a 
Lactobacillus rhamnosus overnight culture.  Optical Density (OD) readings were taken 
at 500nm.    
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Table 13:  Oil-Red-O (ORO) staining and quantification by spectrophotometry of lipid 
content of mature 3T3-L1A cells treated with filtered spent broth (FSB) from a 
Lactobacillus rhamnosus overnight culture  
  
 
 
ORO lipid content per well for FSB treatment of Cell culture.  The optical density 
measurements were taken via spectrophotometry set to 500nm.   
 
Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus Overnight Culture 
in Enterocytes 
FSB was used to treat Caco-2 cell culture to measure differences in protein 
expression for transcription factors important in lipid transport.  Western blot analysis of 
SREBP-1c indicated that the FSB treatment did not affect protein expression (Table 14, 
Figure 16).  MTTP protein showed an increased expression of 1.2 fold during the 100 
µl/ml FSB treatment (Table 15, Figure 17). 
 
 
 
 
FSB concentration (µl/ml media) Optical Density Measured at 500nm 
0µl/ml 1.16 
10µl/ml 1.41 
25µl/ml 1.41 
50µl/ml 1.03 
75µl/ml 0.9 
100µl/ml 0.64 
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Figure 16:  Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus 
overnight culture on the expression of SREBP-1c in Caco-2 cells.  Figure 16a is the 
western blot image.  Figure 16b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 0 
µl/ml.  Each bar represents mean fold changes.  The Y-axis has been set to 1 to 
normalize the graph to the control. 
Table 14:  Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus 
overnight culture on the expression of SREBP-1c in Caco-2 cells 
a Expression values are mean fold changes.  n = 4.  Mean fold changes are of protein 
expression relative to the positive control. 
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FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.935  
25µl/ml  1.086  
50µl/ml  1.117  
75µl/ml  1.063  
100µl/ml  0.929  
0       0     10    10    25    25   50    50    75    75   100  100  μl/ml FSB 
Figure 16a 
Figure 16b 
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Figure 17:  Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus 
overnight culture on the expression of MTTP in Caco-2 cells.  Figure 17a is the western 
blot image.  Figure 17b represents the quantification of the protein expression.  
Expression is presented as fold change relative to the control FSB concentration of 0 
µl/ml.  Each bar represents mean +/- standard deviation.  The Y-axis has been set to 1 
to normalize the graph to the control.   
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Figure 17a 
 0       10     25      50     75    100  µl/ml FSB 
Figure 17b 
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Table 15:  Effect of Filtered Spent Broth (FSB) from a Lactobacillus rhamnosus 
overnight culture on the expression of MTTP in Caco-2 cells 
a Expression values are mean fold changes.  n = 2.  Mean fold changes are of protein 
expression relative to the positive control. 
 
   
 
  
FSB concentration (µl/ml media)  Relative expressiona  
0µl/ml  1  
10µl/ml  0.943  
25µl/ml  1.151  
50µl/ml  1.073  
75µl/ml  1.065  
100µl/ml  1.224  
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CHAPTER 4 
DISCUSSION 
   With the obesity epidemic rising, more needs to be understood about the 
disease and possible new treatments.  This study was performed to gain possible 
insight into the therapeutic uses of probiotics.  The study tested a novel probiotic 
against a cell culture model of adipogenesis.  Protein expression changes attributed to 
probiotic treatment of the cells.  Western blot analysis showed that filtered spent broth 
(FSB) treatment upregulated key adipogenic transcription factors, PPAR³ , C/EBP±, and 
ATGL expression.  Contrasting findings have been reported where the adipogenic 
transcription factors were downregulated by probiotic treatment. Other probiotic anti-
obesity studies have given contradictory findings to what was observed in the present 
study.  Moon et al. (2012) showed that cytoplasmic fraction and cell free cultured 
medium of Weisella koreensis lowered lipid accumulation and mRNA expression of key 
transcription factors in differentiating adipocyte cell culture.  Another study used cell 
extract of Lactobacillus brevis OPK-3 to downregulate expression of PPAR³  and 
C/EBP± (Park et al. 2014). By comparing the findings of this study to previously 
reported findings, it becomes clearer that different probiotics elicit strain specific 
responses.   
   
Once the Western blot analysis indicated that there could be PPAR³  agonistic 
qualities associated with the FSB treatment, the next step was to test the FSB treatment 
against known PPAR³  agonists.  Since rosiglitazone was already being used to produce 
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high differentiation in the cell culture, it was chosen for the PPAR³  agonist.  The results 
indicated that FSB treatment was able to upregulate PPAR³  to levels comparable to 
rosiglitazone.  The factor in FSB was inactivated by heat and is likely to be a heat labile 
protein or biomolecule.  This is important in the search for new anti-diabetic drugs.  
Rosiglitazone is a potent drug against insulin resistance associated with Type 2 
Diabetes (Gerstein et al. 2006).  The drawback is that this drug can cause severe side 
effects.  It is possible that the compound in the FSB treatment could be used to replace 
rosiglitazone, or a probiotic regimen could be used in conjunction with rosiglitazone to 
improve effectiveness while lowering drug dosage. 
The gastrointestinal lumen stands as the physical barrier between the body and 
the gut microbiota.  Studies by Kim (Kim et al. 2013) and Marcil (Marcil et al. 2003) have 
shown that the microbiome and biomolecules are able to interact with the gastric lumen 
to alter protein expression.  This interaction is not well understood, but it could have an 
impact on how lipids are transported and stored.  In the present study, FSB did not 
affect the expression of proteins SREBP-1c and MTTP that are known to play important 
roles in lipid transport.  However, some probiotics have been shown to elicit strain 
specific responses of the gastrointestinal epithelial cells.  In the study by Putaala et al. 
(2010), cell to cell adhesion, superoxide metabolism, and MAPK pathway were all 
regulated differently by the various probiotic bacteria.  
The Oil-Red-O (ORO) staining in the present study showed that lipid content rose 
with the 10 and 25 µl/ml and then dropped with higher FSB doses.  50 µl/ml and above 
FSB treatments were observed to cause cell death during the ORO study.  One 
drawback with ORO is that it only measures the amount of lipid content in each well 
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instead of measuring lipid content within each cell.  Since there was cell death involved 
with some batches of the FSB treatment, this could have led to lower total lipid content 
readings.   
An interesting observation during this study was that certain FSB treatments 
seemed to cause increased cell culture detachment and death.  This was not observed 
with the first batch of FSB treatment made, but in some subsequent batches cell death 
was observed.  Fresh MRS broth treatment was explored as a possible control 
treatment for FSB, but it was determined that MRS caused high cell death among the 
cells being cultured.  It is possible that during some of the FSB preparations, the 
spectrophotometer that was used to measure optical density (OD) reading was not set 
to the same wavelength as previous batches.  This could have given a premature 
reading of 2.0 OD leading to shortened growth times for some FSB treatments.  Fresh 
MRS broth and FSB that had a shortened bacterial growth time seemed to produce high 
cell death when used as cell culture treatment.  This observation led to the examination 
of the ingredients that make up MRS broth.  When looking at the ingredients listed in 
MRS broth, one ingredient stood out as being a possible culprit for the cell death.  
Sodium acetate is included in MRS broth as both an energy source to the bacteria and 
a selective agent to prevent certain other organisms from growing in the broth.  Sodium 
acetate has been shown to have cytotoxic effects in high doses (Sun et al. 2005).  
Normally the L. rhamnosus isolate would use up the sodium acetate as an energy 
source, but due to shorter incubation times for some of the FSB treatment batches, the 
bacteria did not have the time to break down the sodium acetate present in the broth.  
This could explain the decrease in cell viability associated with some of the FSB 
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batches with shorter bacterial incubation periods, as well as explain the high cytotoxicity 
of fresh MRS broth.  It would be beneficial to mix an MRS broth without sodium acetate 
to see if the probiotic bacteria will grow, and if the broth causes high cell culture death. 
Cell death caused by possible sodium acetate cytotoxicity could explain 
irregularities in the Oil-Red-O (ORO) results.  Quantification of ORO actually measures 
lipid content per cell culture well instead of lipid content per cell culture cell.  As the FSB 
treatment levels increased higher cell death was observed.  This means that the 75 and 
100µl/ml treatments induced higher cell death than the control.  The resultant difference 
in cell numbers would mean that the high treatment wells had lower density of cells 
contributing to lower lipid content readings.  Another possibility is that the cells were 
stressed by the cytotoxic compound.  This stress could have hampered the adipocyte’s 
ability to store lipids.  The higher FSB treatments would have put higher stress on the 
cells, thereby giving the effect of lower lipid content with higher FSB treatment.   
A recent study showed that Lactobacillus rhamnosus secretes proteins into 
surrounding media as the bacteria grows (Sanchez et al. 2009).  The protein expression 
changes caused by FSB treatment with no changes seen from the CE treatment 
suggest that this isolate secretes a possible biomolecule into the surrounding 
environment that are cause these changes.  Inactivation of the FSB by heat suggests 
that this biomolecule is heat labile.  The source that was used to isolate the potential 
probiotic tested in this study was by all accounts, novel, and this specific L. rhamnosus 
strain could have peculiar characteristics, perhaps contradictory to other previously 
isolated strains. 
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At first thought, the idea of reducing adipogenesis may seem like the correct way 
to battle the continuing obesity epidemic.  The problem with this idea is that obesity is 
considered a state of energy excess, whereby caloric intake is higher than energy 
expenditure.  If adipogenesis is reduced without fixing the energy imbalance then the 
excess glucose and fatty acids will continue to build in the blood and be forced to be 
stored in the liver and other tissues.  This can cause hepatomegaly, fatty liver disease, 
hyperlipidemia and other diseases characterized by increased circulating or improperly 
stored lipids (Rosen et al. 2000).  The more appropriate approach is to increase 
adipogenesis to allow for proper clearance of circulating lipids, while at the same time 
addressing the energy imbalance.  This study was designed to test the ability of a novel 
probiotic milk isolate L. rhamnosus to influence adipogenesis in vitro.  Indeed, 
biomolecules present in spent culture from this isolate were able to increase 
adipogenesis when administered to differentiating adipocytes. 
In summary, an overnight filtered spent broth (FSB) culture of a Lactobacillus 
rhamnosus isolate from “amabere amaruranu”, Kenyan traditional cultured milk 
preparation upregulated , PPAR³ , C/EBP±, and ATGL adipogenic transcription factors.  
The active ingredient in the FSB seemed to be heat-labile in nature.  Finally, because 
the FSB shared similar PPAR³  agonistic ability as rosiglitazone, a diabetic drug, there 
might be a possibility of use of this biomolecule in development of new therapies. 
Future research to define the limits and potential of any treatment with this 
probiotic needs to be conducted.  The biomolecule that causes the observed changes in 
protein expression level and differentiation needs to be isolated and identified.  This 
biomolecule could be very important in finding novel treatments for type 2 diabetes by 
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its potential to upregulate PPAR³  similar to current treatments.  The probiotic itself 
should be tested in an animal model of obesity to further investigate the efficacy of a 
probiotic approach to obesity treatment.  If able to be isolated, the biomolecule will have 
to go through cell culture testing to show that this compound causes the same effects 
as observed in this study, proving that it is the active agent in the FSB treatment shown 
in the present study.  
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